Completed PHASE3 INTERVENTIONAL NCT00036374

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis

A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis

Sponsor: Centocor, Inc.

Conditions Rheumatoid Arthritis, Juvenile

Interventions Infliximab

Updated 5 times since 2017 Last updated: May 16, 2011 Started: Oct 31, 2001 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00036374, this PHASE3 trial focuses on Rheumatoid Arthritis, Juvenile and remains completed. Sponsored by Centocor, Inc., it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centocor, Inc.

Data source: Centocor, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.